pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
EGFR · news · pharmadog
← back to EGFR
News · EGFR
113
stories
2h
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
7d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
8d
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
9d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
9d
Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact
biospace
12d
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
13d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
13d
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
endpoints
13d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
16d
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
19d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
23d
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Jul 27, 26
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
Jul 24, 26
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 17, 26
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
fiercebiotech
Jul 15, 26
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
biopharma dive
Jul 14, 26
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
Jul 6, 26
Bristol Myers details Krazati confirmatory study failure in colorectal cancer
endpoints
Jun 4, 26
STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
stat
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
May 31, 26
Akeso, Summit drug extends survival in closely watched lung cancer trial
biopharma dive
May 13, 26
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
onclive
May 13, 26
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
onclive
May 13, 26
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
onclive
May 13, 26
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
onclive
May 13, 26
Future Directions in Metastatic Castration-Resistant Prostate Cancer
onclive
May 13, 26
Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer
onclive
← prev
page 1 of 4
next →
